The European Commission has approved Trodelvy (sacituzumab govitecan) as a first-line treatment for adults with unresectable or metastatic triple-negative breast cancer who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1 or PD-L1 inhibitor therapy.
The decision introduces an antibody–drug conjugate into the first-line metastatic TNBC setting for this specific population. It is based on results from the phase III ASCENT-03 trial, which compared sacituzumab govitecan with chemotherapy in patients whose disease was not eligible for PD-(L)1 inhibitor-based treatment.
A New First-Line Option for a High-Unmet-Need Population
Triple-negative breast cancer lacks estrogen receptor, progesterone receptor, and HER2-targeted treatment options. In the metastatic setting, treatment selection is shaped by PD-L1 status, germline BRCA status, prior therapy, disease burden, comorbidities, and the need to balance disease control with treatment toxicity.
For patients who are not candidates for PD-1 or PD-L1 inhibitors, first-line treatment has largely relied on chemotherapy-based approaches. The new authorization positions sacituzumab govitecan as a chemotherapy-free monotherapy option in this setting.
The approval applies across the 27 European Union member states, as well as Norway, Iceland, and Liechtenstein.
Read About Sacituzumab govitecan on OncoDaily
What Did ASCENT-03 Show?
ASCENT-03 was a randomized phase III trial evaluating sacituzumab govitecan against physician’s-choice chemotherapy as first-line therapy for patients with unresectable locally advanced or metastatic TNBC who were not candidates for PD-1 or PD-L1 inhibitor treatment.
The trial met its primary endpoint of progression-free survival.
Sacituzumab govitecan (Trodelvy) reduced the risk of disease progression or death by 38% compared with chemotherapy:
- Hazard ratio: 0.62
- P value: <0.0001
- Median PFS: 9.7 months with sacituzumab govitecan
- Median PFS: 6.9 months with chemotherapy
The study used a crossover design, allowing participants assigned to chemotherapy to receive sacituzumab govitecan after disease progression. This design is clinically relevant for patient access, but it can make interpretation of overall survival comparisons more complex.
Read About ASCENT-03 Trial on OncoDaily
Why This Approval Matters
The approval moves a TROP2-directed antibody–drug conjugate into an earlier stage of metastatic TNBC treatment in Europe.
Sacituzumab govitecan delivers the topoisomerase I inhibitor payload SN-38 through an antibody directed against TROP2, a cell-surface antigen expressed in many epithelial cancers. Its activity may also extend beyond antigen-positive cells through a bystander effect within the tumor microenvironment.
For clinicians, the decision creates a new first-line treatment pathway for patients who are not eligible for PD-(L)1 inhibitors. It also highlights the increasing role of antibody–drug conjugates in HER2-negative metastatic breast cancer.
Where Does ASCENT-04 Fit?
Gilead has also submitted an application in Europe for sacituzumab govitecan plus pembrolizumab in patients with PD-L1-positive unresectable locally advanced or metastatic TNBC, based on the phase III ASCENT-04 trial.
That application remains under review.
If authorized, the combination could expand the role of sacituzumab govitecan in first-line metastatic TNBC across PD-L1-defined populations:
- Sacituzumab govitecan alone for patients not eligible for PD-(L)1 inhibitors
- Sacituzumab govitecan plus pembrolizumab for PD-L1-positive disease, pending regulatory review
These approaches should not be considered interchangeable. Treatment decisions will continue to depend on biomarker testing, indication-specific approvals, clinical factors, and local treatment access.
Safety Considerations Remain Central
Sacituzumab govitecan is associated with clinically important hematologic and gastrointestinal toxicities. Neutropenia and diarrhea are among the key adverse events requiring proactive monitoring and supportive care.
Treatment teams should follow the approved product information for blood-count monitoring, growth factor prophylaxis when clinically indicated, management of febrile neutropenia, early treatment of diarrhea, antiemetic prophylaxis, dose modifications, and assessment of individual risk factors.
The approval expands treatment options, but it also reinforces the importance of experienced supportive care during antibody–drug conjugate treatment.
What Changes in Europe?
The EC decision establishes sacituzumab govitecan as a first-line monotherapy option for a defined subgroup of metastatic TNBC: patients who are not candidates for PD-1 or PD-L1 inhibitor therapy.
The most immediate clinical impact will likely be in treatment discussions for patients with PD-L1-ineligible or otherwise immunotherapy-ineligible disease, where the ASCENT-03 data showed a substantial progression-free survival advantage over chemotherapy.
Overall survival data, patient-reported outcomes, toxicity management, treatment sequencing, and results from ongoing first-line studies will remain important in defining the broader role of sacituzumab govitecan in metastatic TNBC care.